H5N1 influenza vaccine, AUDENZ™, receives FDA approval

Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. Food and Drug Administration (FDA) has approved AUDENZa (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1). AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza ["]

The post H5N1 influenza vaccine, AUDENZa, receives FDA approval appeared first on Outbreak News Today.